I-Tildrakizumab imakethwa ngu ILanga Pharma ngaphansi kwegama lokuhweba elithi Ilumya, futhi ligunyazwe i-FDA ngoMashi 2018 ngemva kokuhlaziywa kwedatha evela ku-Phase III yokuhlolwa kwezikhungo eziningi, okungahleliwe, okulawulwa yi-placebo i-RESURFACE 1 kanye ne-RESURFACE 2. Zombili izifundo zifinyelele isiphetho esiyinhloko okungenani esingu-75% yokususwa kwesikhumba njengoba kukalwa ngezikolo ze-PASI ne-PGA. Ukugunyazwa kwe-European Commission kanye ne-TGA, e-Australia kwafika ngo-September 2018. Ngokusekelwe emtholampilo kanye nokusebenza kahle kwezindleko ze-Ilumya, NICE, UK incose ukusetshenziswa kwe-tildrakizumab ngo-2019 ekwelapheni i-psoriasis enzima.
I-Plaque psoriasis yisifo sokuvuvukala kwe-autoimmune esiphatha abantu abacishe babe yizigidi eziyi-125 emhlabeni jikelele. Izimpawu ezivamile zihlanganisa izilonda ezinamabala abomvu ezingxenyeni zesikhumba, okuhlanganisa amadolo, indololwane, isikhumba sekhanda noma umhlane ongezansi, ezivuvukalayo futhi ezilumayo futhi ezibuhlungu. U-80% wabantu abathola lesi sifo unezimpawu ezimaphakathi kuya kwezimaphakathi kanti u-20% unesimo esibi kakhulu isifo lapho ama-plaque eqhekeka okuholela ekopheni kanye nokungakhululeki okwengeziwe. I-Psoriasis inemithelela ebalulekile kwezenhlalo nezomnotho ezigulini eziphethwe yilesi sifo. Izinga lempilo lithinteka kakhulu njengoba isiguli siqala ukudangala kanye nokuthambekela kokuzibulala ngenxa yabantu 'abavamile' abagcina ukuqhelelana nabantu abanaleli gciwane okubenza bazizwe benamahloni futhi babashiye becindezeleke nakakhulu.
Izinhlobo eziningi zokwelapha ze-psoriasis ziyatholakala kuye ngobunzima bezimpawu. Kuhlanganisa ukwelapha ngezihloko kusetshenziswa izigcobo zesikhumba, i-phototherapy, lapho isikhumba sichayeka ekukhanyeni kwe-UV kanye nemithi yesistimu ehlanganisa amakhemikhali kanye nezinhlangano zebhayoloji ezifana namasosha omzimba.
Izindlela zokwelapha zebhayoloji ze-psoriasis zifaka amasosha omzimba anjenge-etanercept, adalimumab, infliximab, ustekinumab kanye i-tildrakizumab ukubala abambalwa. Lawa ma-antibody asebenza ngokunciphisa ukuvuvukala ngokuqondisa amangqamuzana asebenza ngokweqile amasosha omzimba. Ukwelashwa kwebhayoloji kuvame ukusetshenziswa ezimeni ezinzima ze-psoriasis lapho iziguli zingaphenduli kwezinye izindlela zokwelapha ezishiwo ngenhla.
Phakathi kwezinhlangano zebhayoloji ezisetshenziselwa ukwelashwa kwe-psoriasis, i-tildrakizumab ibonakala iphumelela kakhulu mayelana nokunciphisa izimpawu kanye nezindleko zayo. Imiphumela yokuhlolwa komtholampilo ibonise ukuthi i-tildrakizumab ithuthukisa i-plaque enzima psoriasis uma kuqhathaniswa ne-placebo noma i-etanercept enentuthuko ephawulekayo ebonakala emavikini angama-28. Ngaphezu kwalokho, i-tildrakizumab ibonakala isebenza njenge-adalimumab ne-ustekinumab. Mayelana nezindleko, i-tildrakizumand ibiza kakhulu ngo-18% kune-adalimumab nyanga zonke okuholela ekwehliseni izindleko okubalulekile esikhathini esiyiminyaka emihlanu.
I-Tildrakizumab imakethwa ngu Sun Amakhemisi ngaphansi kwegama lokuhweba Ilumya, futhi sigunyazwe i-FDA ngoMashi 2018 ngemva kokuhlaziywa kwedatha evela ku-Phase III yokuhlolwa komtholampilo kwezikhungo eziningi, okungahleliwe, okulawulwa yi-placebo i-RESURFACE 1 kanye ne-RESURFACE 2. Zombili izifundo zifinyelele isiphetho esiyinhloko okungenani esingu-75% sokusulwa kwesikhumba njengoba kukalwa. nge-PASI kanye nezikolo ze-PGA. Ukugunyazwa kwe-European Commission kanye ne-TGA, e-Australia kwafika ngo-September 2018. Ngokusekelwe emtholampilo kanye nokusebenza kahle kwezindleko ze-Ilumya, NICE, UK incose ukusetshenziswa kwe-tildrakizumab ngo-2019 ekwelapheni i-psoriasis enzima.
***
